Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?

Sun Young Cho,Cheol-In Kang,Jungok Kim,Young Eun Ha,Doo Ryeon Chung,Nam Yong Lee,Kyong Ran Peck,Jae-Hoon Song
DOI: https://doi.org/10.1128/AAC.01682-13
IF: 5.938
2014-01-01
Antimicrobial Agents and Chemotherapy
Abstract:A retrospective study was conducted to evaluate the efficacy of levofloxacin in the treatment of Stenotrophomonas maltophilia bacteremia. The 30-day mortality rates were similar between the trimerthoprim-sulfamethoxazole (TMP-SMX) and levofloxacin treatment groups. Adverse events related to antibiotics occurred more frequently in patients receiving TMP-SMX, and recurrent bacteremia due to levofloxacin-resistant S. maltophilia strains developed in patients treated with levofloxacin. Our data suggest that levofloxacin can be a useful alternative option for treating S. maltophilia infections.
What problem does this paper attempt to address?